| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4026130 | Ophthalmology | 2014 | 6 Pages |
Abstract
Polymorphisms in the VEGFR2/KDR gene significantly influence visual outcome in patients receiving ranibizumab treatment for neovascular AMD. This study shows that genetic variation partially explains the wide range of response to ranibizumab treatment, which in the future might help clinicians tailoring medical interventions to individual needs.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Manuel M. MD, Freekje MD, Philipp S. MD, Dzenita MD, Peter PhD, Carel B. MD, PhD, Bernd MD, Christian MD, Anneke I. PhD, Sascha MD,